ACE-083 is a follistatin-based therapeutic agent designed for localized activity that increases muscle mass by binding myostatin and related muscle-regulatory factors, and although ACE-083 demonstrated consistent muscle volume increases across multiple clinical trials, its lack of functional improvement in phase II facioscapulohumeral muscular dystrophy studies led to discontinuation of its development for FSHD.